# Advancing genomics through the AMD Genomics Consortium

> **NIH NIH R01** · CASE WESTERN RESERVE UNIVERSITY · 2020 · $419,416

## Abstract

Age-related macular degeneration (AMD) is one of the leading causes of blindness in the elderly. It has a
significant impact on the independence, quality of life, and healthcare costs for those afflicted and the
additional social cost on caregivers and family members is incalculable. There is substantial variability in the
AMD phenotype and the primary treatment, to repeatedly inject anti-VEGF antibodies into the eye of those
severely affected, is effective in only a subset of individuals. Thus a better understanding of the underlying
causes of AMD is needed to help guide development of more universal and effective treatments and potential
preventive measures for AMD.
AMD is strongly influenced by genomic variation. Through the initial funding period of this proposal, we
supported the development of the International AMD Genomics Consortium (IAMDGC), which brought together
26 research groups from around the world. The IAMDGC has increased the known genomic loci from 12 to 52
and successfully performed a new and larger genotyping study focused on rarer variation using a high-density
genome-wide SNP chip with exome content. This collaborative effort has also spawned numerous additional
interesting avenues of research that we now need to explore in more detail through the renewal of this highly
successful project. While the current genotypic dataset of over 50,000 samples has much left to be mined,
expansion of the available samples, with a particular focus on families and minority samples, is necessary if we
are to achieve our stated goal of completely defining the genetic architecture of AMD. To address these
unresolved issues we propose four specific aims: 1) Expand the IAMDGC resource with additional datasets
and expansion of current datasets, with a focus on family data and diverse genetic ancestry; 2) Expand the
range of clinical diagnostic measures (e.g. fundus photos, OCT measures), biomarker, comorbidity, and
covariate data associated with the samples; 3) Use an analytical hub infrastructure to perform detailed
analyses of these data; and 4) Support the logistics and administration of the IAMDGC.

## Key facts

- **NIH application ID:** 9910404
- **Project number:** 5R01EY022310-07
- **Recipient organization:** CASE WESTERN RESERVE UNIVERSITY
- **Principal Investigator:** Jonathan L Haines
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $419,416
- **Award type:** 5
- **Project period:** 2012-04-01 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9910404

## Citation

> US National Institutes of Health, RePORTER application 9910404, Advancing genomics through the AMD Genomics Consortium (5R01EY022310-07). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/9910404. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*